Your browser doesn't support javascript.
loading
Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.
Reinert, Tomás; de Paula, Bruno; Shafaee, Maryam Nemati; Souza, Pedro Henrique; Ellis, Matthew J; Bines, José.
Afiliação
  • Reinert T; Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil; Programa de Pós-Graduação em Ciências Médicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • de Paula B; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Shafaee MN; Lester and Sue Smith Breast Cancer Center, Baylor College of Medicine, Houston Texas, USA.
  • Souza PH; Hospital do Câncer de Barretos, Barretos, Brazil.
  • Ellis MJ; Lester and Sue Smith Breast Cancer Center, Baylor College of Medicine, Houston Texas, USA. matthew.ellis@bcm.edu.
  • Bines J; Instituto Nacional de Câncer (INCA-HCIII), Rio de Janeiro, Brazil.
Chin Clin Oncol ; 7(3): 25, 2018 Jun.
Article em En | MEDLINE | ID: mdl-30056727
The estrogen receptor (ER) has been targeted for breast cancer treatment for over a century, but many challenges persist. ER-positivity identifies the largest breast cancer subgroup, and ER-directed therapies prolong survival and improve symptoms in the advanced setting with a very favorable side effect profile. Treatment strategies have included decreasing estrogen synthesis and modulating or degrading the ER. However, ER+ breast cancer once diagnosed in the advanced setting still represents an incurable condition. Many efforts are ongoing to circumvent resistance mechanisms with a few strategies already incorporated into clinical practice such as the combination of endocrine agents with drugs that interfere with other signaling pathways and cell-cycle progression. Important questions remain as how best to select each available strategy, how to sequence them and ultimately how to extend benefits to the largest number of patients in need.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Receptor ErbB-2 / Antineoplásicos Hormonais Limite: Female / Humans Idioma: En Revista: Chin Clin Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Receptor ErbB-2 / Antineoplásicos Hormonais Limite: Female / Humans Idioma: En Revista: Chin Clin Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: China